You don’t search. It finds.
Discovery for the Next Era of Global Pharma.
Thousands of clinical assets are advancing in China right now. Lelia tells you which ones matter to your pipeline and connects you directly to the people behind them.
Risk Assessment: Invisible Market
China: The Opportunity Hidden in Plain Sight.
China is the 2nd largest clinical trial source in the world, generating oncology and immunology breakthroughs every single month. Yet for most Western BD and strategy teams, this data is effectively invisible. Fragmented across localized registries, locked in Mandarin documentation, and isolated from global databases.
Information Asymmetry
Localized clinical findings take 18–24 months to reach English-speaking market monitors.
Linguistic Barrier
Over 90% of raw clinical documentation is never translated into standardized English formats.
Fragmented Intelligence
Data points exist in isolation, lacking the cross-trial reasoning required for BD&L valuation.
China out-licensing deal value in 2025
Of global outlicensing deal value now comes from China
Chinese assets out-licensed in 2024 alone
Select your focus
Active Knowledge Infrastructure
It reasons, not just retrieves.
Lelia operates as a connected intelligent data layer thinking across datasets to find clinical alpha in milliseconds, not months.
01 / Find
Find
You define your context. Lelia surfaces what’s relevant — mechanism adjacencies, unpartnered assets, competitive threats entering your indication. No proactive searching required.
02 / Access
Access
Access to the people and details behind the assets that matter.
03 / Move Fast
Move Fast
Global drug development moves faster when the right assets find the right partners.
Built for BD and strategy teams
Business Development
Find and access unpartnered Chinese assets before they reach your competitors’ desks.
Clinical Strategy
Understand what’s advancing in China across your indication before it changes your development plan.
Competitive Intelligence
Track Chinese programs entering your market at the speed they’re actually moving.
Portfolio & Corporate Development
Map the global asset landscape with China included, not as an afterthought.
The Era of Static Databases is Over.
Get started
Ready to illuminate the blind spots?
Join the BD and strategy teams using Lelia to stay ahead of what’s coming out of China.
The Team
The people behind Lelia.
Lennart Wendt
CEO
Pharma background in market access at Bayer, combined with hands-on hardware fundraising experience.
Julia Schimanietz
COO
Entrepreneur at the intersection of biotech and food innovation. Brings hands-on venture experience and public fundraising expertise.
Rouven Glauert
CTO
Physicist turned AI consultant. Nearly 5 years at idalab consulting AI for Life Science, from data science to senior strategy.